These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37593116)

  • 1. Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma.
    Kumar S; Nadda N; Quadri A; Kumar R; Paul S; Tanwar P; Gamanagatti S; Dash NR; Saraya A; Shalimar ; Nayak B
    Front Genet; 2023; 14():1235260. PubMed ID: 37593116
    [No Abstract]   [Full Text] [Related]  

  • 2. TP53 R249S mutation detected in circulating tumour DNA is associated with Prognosis of hepatocellular carcinoma patients with or without hepatectomy.
    Shen T; Li SF; Wang JL; Zhang T; Zhang S; Chen HT; Xiao QY; Ren WH; Liu C; Peng B; Ji XN; Yang Y; Lu PX; Chen TY; Yu L; Ji Y; Jiang DK
    Liver Int; 2020 Nov; 40(11):2834-2847. PubMed ID: 32594568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus-associated hepatocellular carcinoma from India: role of viral genotype and mutations in CTNNB1 (beta-catenin) and TP53 genes.
    Vivekanandan P; Torbenson M; Ramakrishna B
    J Gastrointest Cancer; 2011 Mar; 42(1):20-5. PubMed ID: 20963515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
    Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
    Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity.
    Huang A; Zhang X; Zhou SL; Cao Y; Huang XW; Fan J; Yang XR; Zhou J
    J Cancer; 2016; 7(13):1907-1914. PubMed ID: 27698932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.
    Campani C; Imbeaud S; Couchy G; Ziol M; Hirsch TZ; Rebouissou S; Noblet B; Nahon P; Hormigos K; Sidali S; Seror O; Taly V; Ganne Carrie N; Laurent-Puig P; Zucman-Rossi J; Nault JC
    Gut; 2024 Oct; 73(11):1870-1882. PubMed ID: 39054058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of
    Javanmard D; Najafi M; Babaei MR; Karbalaie Niya MH; Esghaei M; Panahi M; Safarnezhad Tameshkel F; Tavakoli A; Jazayeri SM; Ghaffari H; Ataei-Pirkooh A; Monavari SH; Bokharaei-Salim F
    Infect Agent Cancer; 2020; 15():37. PubMed ID: 32514293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide association study of the TP53 R249S mutation in hepatocellular carcinoma with aflatoxin B1 exposure and infection with hepatitis B virus.
    Han C; Yu T; Qin W; Liao X; Huang J; Liu Z; Yu L; Liu X; Chen Z; Yang C; Wang X; Mo S; Zhu G; Su H; Li J; Qin X; Gui Y; Mo Z; Li L; Peng T
    J Gastrointest Oncol; 2020 Dec; 11(6):1333-1349. PubMed ID: 33457005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of CTNNB1 and TP53 variability in patients with hepatocellular carcinoma and occult hepatitis B virus infection.
    Saitta C; Lanza M; Bertuccio A; Lazzara S; Navarra G; Raimondo G; Pollicino T
    Cancer Genet; 2015 Oct; 208(10):513-6. PubMed ID: 26341700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma.
    Wang J; Huang A; Wang YP; Yin Y; Fu PY; Zhang X; Zhou J
    Ann Transl Med; 2020 Mar; 8(5):237. PubMed ID: 32309384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
    Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
    Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
    J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand.
    Galy O; Chemin I; Le Roux E; Villar S; Le Calvez-Kelm F; Lereau M; Gouas D; Vieco B; Suarez I; Navas MC; Chevallier M; Norder H; Srivatanakul P; Karalak A; Sangrajrang S; Trépo C; Hainaut P
    Hepat Res Treat; 2011; 2011():697162. PubMed ID: 21760996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic characterization of early-stage hepatocellular carcinoma patients with Hepatitis B using circulating tumor DNA.
    Lin D; Luo R; Ye Z; Wei Q; Bae H; Juon HS; Hann HW; Posey J; Wang C
    Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102161. PubMed ID: 37307947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
    Huang FY; Wong DK; Tsui VW; Seto WK; Mak LY; Cheung TT; Lai KK; Yuen MF
    BMC Cancer; 2019 Aug; 19(1):789. PubMed ID: 31395065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas.
    Amaddeo G; Cao Q; Ladeiro Y; Imbeaud S; Nault JC; Jaoui D; Gaston Mathe Y; Laurent C; Laurent A; Bioulac-Sage P; Calderaro J; Zucman-Rossi J
    Gut; 2015 May; 64(5):820-9. PubMed ID: 25021421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation-Selected Amplification droplet digital PCR: A new single nucleotide variant detection assay for TP53
    Hu L; Ji YY; Zhu P; Lu RQ
    Anal Chim Acta; 2024 Aug; 1318():342929. PubMed ID: 39067934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma.
    Ge Z; Helmijr JCA; Jansen MPHM; Boor PPC; Noordam L; Peppelenbosch M; Kwekkeboom J; Kraan J; Sprengers D
    Transl Oncol; 2021 Jul; 14(7):101073. PubMed ID: 33915518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.